INTRODUCTION {#sec1-1}
============

Respiratory management of patients with corona virus disease 2019 (COVID-19) is both complex and highly nuanced.\[[@ref1]\] Although most patients with COVID-19 develop mild or no symptoms, a smaller proportion (up to 15%) experience progressive hypoxic respiratory failure requiring escalating levels of oxygen support.\[[@ref2]\] Significant accumulated experience in caring for patients with SARS-CoV-2 pulmonary illness resulted in the recognition of major respiratory failure patterns, the benefits of early proning, and the importance of a step-wise escalation in levels of invasiveness across the entire spectrum from nasal cannula to extracorporeal support.\[[@ref2][@ref3][@ref4]\] Given substantial heterogeneity among various algorithmic approaches to oxygen therapy and the need for both standardization and optimization of clinical management methodologies, the Joint ACAIM-WACEM COVID-19 Clinical Management Taskforce (CCMT) set out to establish and publish a unified approach to the patient who presents with SARS-CoV-2 lower respiratory tract infection (LRTI). In addition, the CCMT hopes that a protocol-driven strategy will lead to conservation of precious healthcare resources, such as intensive care beds and ventilators, by eliminating unnecessary interventions and various other process inefficiencies.

Clinical rationale {#sec2-1}
------------------

The Joint ACAIM-WACEM CCMT is a multidisciplinary group with participants from multiple countries and significant collective expertise in clinical management of COVID-19. Based on our shared experiences, we set out to design and optimize a uniform approach toward patients suffering from SARS-CoV-2 LRTI. The primary goal of the CCMT was to ensure broad applicability of the resultant treatment algorithms across diverse clinical settings, regardless of resource availability \[[Table 1](#T1){ref-type="table"}\]. The secondary goal was to produce a comprehensive, evidence-based resource that will provide clinicians with an easy-to-use and powerful set of tools to manage COVID-19 patients with LRTI and respiratory failure. Multiple sources were utilized when compiling this collection of algorithms and tables.\[[@ref2][@ref5][@ref6][@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20]\]

###### 

Comparison between resource-abundant and resource-limited health-care settings

  Setting/environment/safety      Resource abundant + patient centered   Resource limited + HCP centered
  ------------------------------- -------------------------------------- ---------------------------------
  Phase of pandemic               1, 2                                   3, 4
  Infrastructure                  Adequate                               Average
  Hospital occupancy              Low                                    High
  Surge ICU beds                  No                                     Yes
  Regular health-care providers   Yes                                    No
  Dedicated CCM services          Yes                                    No

The joint ACAIM-WACEM COVID-19 Clinical management Taskforce recognizes that there exist significant regional variations in terms of health-care resources, including considerations related to infrastructure, capacity, clinical skillset, equipment, access/availability, and other resources essential for patient care. ICU: Intensive care unit, HCP: Health-care provider, CCM: Critical care medicine, COVID-19: Coronavirus disease 2019

The working hypothesis adopted by the CCMT is that in COVID-19, the disease caused by SARS-CoV-2 manifests primarily as an oxygen diffusion problem rather than as alterations involving ventilation-perfusion (V/Q) mismatch, low fraction of inspired oxygen (FiO~2~), or hypoventilation.\[[@ref1][@ref3][@ref4][@ref11]\] Consequently, we advocate that initial attempts to address the oxygenation-related impairment should include low-flow nasal cannula (LFNC) and reservoir masks, with progressive escalation to high-flow nasal cannula (HFNC) before implementing awake proning or non-invasive positive pressure ventilation (NIPPV).\[[@ref11][@ref14][@ref15][@ref21][@ref22]\] If these maneuvers and strategies are ineffective, we advocate that a prompt transition is made toward invasive mechanical ventilatory support.\[[@ref14][@ref22][@ref23]\] Cumulatively, the above approach serves to optimize and standardize the overall management of COVID-19 patients with LRTI. The rationale for applying different oxygen therapies to different primary pathophysiologic respiratory problems is presented in [Table 2](#T2){ref-type="table"}.

###### 

Oxygen therapies and respiratory pathophysiology, including evidence-based support

                         Oxygenation   Ventilation   WOB   Solves diffusion   Solves V/Q mismatch   Solves recruitment
  ---------------------- ------------- ------------- ----- ------------------ --------------------- --------------------
  LFNC                   \+            \-            \-    \+                 \-                    \-
  Reservoir mask         ++            \-            +/-   ++                 \-                    \+
  HFNC                   +++           +/-           +/-   +++                \-                    \-
  Awake proning          \+            \+            \-    \-                 ++                    \+
  HFNC + awake proning   +++           ++            \-    ++/(H)             ++/(H)                +/(H)
  CPAP (no O2)           \-            +/-           +/-   \-                 \+                    \+
  CPAP (with O2)         \+            +/-           +/-   \+                 \+                    \+
  NIPPV (no O2)          \-            ++            ++    +/-                \+                    \+
  NIPPV (with O2)        \+            ++            ++    \+                 \+                    \+
  IMV                    ++            ++            ++    ++                 ++                    ++
  IMV + proning          ++            ++            ++    ++                 +++                   +++
  ECLS                   +++           +++           +++   NA                 NA                    NA

H: Based on past evidence, but largely hypothetical in the context of COVID-19 lower respiratory disease. WOB: Work of breathing, LFNC: Low-flow nasal cannula, HFNC: High-flow nasal cannula, V/Q mismatch: Ventilation-perfusion mismatch, CPAP: Continuous positive airway pressure, NIPPV: Noninvasive positive pressure ventilation, IMV: Invasive mechanical ventilation, ECLS: Extracorporeal life support, COVID-19: Coronavirus disease 2019, + / ++ / +++ Denotes the level of available evidence, with \"+/-\" and \"-\" denoting insufficient or lack of supporting evidence, respectively

Patient history and clinical assessment {#sec2-2}
---------------------------------------

Infection with COVID-19 should be suspected in patients presenting with "typical" signs and symptoms including fever, cough, and various degrees of hypoxia,\[[@ref24]\] although clinical manifestations can take a number of other forms, particularly in the elderly population.\[[@ref2]\] Patients with elevated risk of severe disease are older, immunocompromised, morbidly obese, male, or have two or more chronic comorbid conditions.\[[@ref2][@ref24][@ref25][@ref26]\] Additional clinical signs and symptoms associated with severe illness include tachycardia, hyperthermia (≥39°C), encephalopathy, and hemodynamic instability.\[[@ref2][@ref27]\] While a "typical" COVID-19 presentation is seen in the vast majority of cases,\[[@ref2]\] additional specific "red flags" such as the presence of "silent hypoxia" must be kept in mind.\[[@ref27][@ref28][@ref29][@ref30]\] Reliable oxygen saturation measurement (SpO~2~) is the cornerstone of initial risk stratification and disease severity assessment. Patients with normal (or "baseline," if preexisting pulmonary disease exists) SpO~2~are stratified as "low risk," whereas patients with an initial SpO~2~\< 93% (or similar decline below "baseline" levels) require immediate supplemental oxygen therapy.

In addition to a comprehensive COVID-19 laboratory workup,\[[@ref2][@ref31]\] specific factors associated with severe respiratory disease have been identified, including the presence of myalgias, elevated hemoglobin levels, and elevated alanine aminotransferase.\[[@ref2]\] Specific risk assessment tools may be considered including the MuLBSTA\[[@ref32]\] and BCRSS scores.\[[@ref2][@ref33]\] Moreover, laboratory findings of a neutrophil-to-lymphocyte ratio of \>3.3, thrombocytopenia, markedly elevated D-dimer, and early elevations in highly sensitive troponin, are all linked to severe disease and poorer prognosis.\[[@ref2][@ref34][@ref35][@ref36][@ref37]\] Severe COVID-19 may also be associated with elevated risk of thromboembolic events.\[[@ref38]\]

Pertinent diagnostic and clinical monitoring criteria {#sec2-3}
-----------------------------------------------------

Radiographic workup is an important part of the overall COVID-19 patient assessment. The initial chest radiograph shows "typical" diagnostic changes in \>67% of patients, and this may increase to \>95% in cases of severe disease.\[[@ref35]\] Noncontrast computed tomography (NCCT) of the chest may correlate with both the diagnosis and severity of COVID 19, and has a reported sensitivity of \>90% at 2--5 days post-onset of symptoms and 97% sensitivity thereafter.\[[@ref2][@ref39][@ref40]\] If the NCCT findings are suspicious for COVID-19,\[[@ref41]\] low-molecular-weight heparin administration\[[@ref42]\] and hospital admission should be considered. If the NCCT is not suggestive of COVID-19, then contrast-enhanced CT of the chest or V/Q scanning may be considered to rule out other causes of hypoxia.

Specific clinical monitoring criteria, as directly relevant to the current manuscript, can be stratified according to patient/assessment location as well as the overall resource availability \[[Table 3](#T3){ref-type="table"}\]. Within this larger paradigm, several assessment tools need to be introduced, including the SCRUB-60 tool \[[Table 4](#T4){ref-type="table"}\]\[[@ref43][@ref44][@ref45]\] and the SBC tool \[[Table 5](#T5){ref-type="table"}\].\[[@ref46][@ref47][@ref48]\] Finally, the risk of pneumothorax may be elevated in patients on prolonged positive pressure ventilation, necessitating tube thoracostomy placement when indicated.\[[@ref49]\]

###### 

Patient monitoring criteria grouped by both patient location and resource-based considerations

  ----------------------------------------------------------------------------------------------------------------------------------------
  Location                                          Resource abundant                               Resource limited
  ------------------------------------------------- ----------------------------------------------- --------------------------------------
  TRIAGE                                            On arrival\                                     On arrival\
                                                    SpO~2~                                          SpO~2~

  Emergency department (or high-dependency units)   On arrival + every 2 h\                         On arrival + every 4-6 h\
                                                    Prognosticators\                                Prognosticators\
                                                     PaO~2~/FiO~2~: Ideal\                           SpO~2~/FiO~2~: Acceptable\
                                                     SpO~2~/FiO~2~: Quick or used in combination\   Clinical risk stratification\
                                                    Clinical risk stratification\                    SCRB-60\
                                                     SCRB-60\                                        SCRUB-60 wards
                                                     SCRUB-60 ED/wards                              

  High-dependency units or intensive care units     Prognosticators\                                Prognosticators\
                                                     PaO~2~/FiO~2~: Ideal\                           PaO~2~/FiO~2~: Ideal\
                                                    Clinical risk stratification\                    SpO~2~/FiO~2~: Used in combination\
                                                     SCRUB-60\                                      Clinical risk stratification\
                                                     SPS-II/APACHE-II                                SCRUB-60\
                                                                                                     SAPS-II/APACHE-II
  ----------------------------------------------------------------------------------------------------------------------------------------

APACHE-II: Acute Physiology and Chronic Health Evaluation II, ED: Emergency department, FiO2: Fraction of inspired oxygen, SCRB-60: Proposed severity score \[[Table 4](#T4){ref-type="table"}\], SAPS-II: Simplified Acute Physiology Score II, SpO~2~: Peripheral capillary oxygen saturation

###### 

The SCR(U)B-60 tool used for risk stratification of community-acquired pneumonia

  ---------------------------------------------------------------------------------------
  S: SpO2 \<93%
  C: Confusion
  R: Respiratory rate \>30 breaths/min
  U: Urea \>7 mmol/L (\>19 mg/dL)
  B: Blood pressure \<90 mmHg (systolic) or \<60 mmHg (diastolic)
  60: Age 60 years, modified to account for higher mortality in COVID for age ≥60 years
  ---------------------------------------------------------------------------------------

The tool is a modification of the CURB-65 score.\[[@ref43]-[@ref45]\] The basic SCRB score can be supplemented with urea (U) measurement when it becomes available. COVID-19: Coronavirus disease 2019

###### 

The single breath count tool\[[@ref47][@ref48]\]

  ---------------------------------------------------------------------
  Method
   Step 1: Ask patient to take a deep breath
   Step 2: Patient counts from 1 to 30 in a single breath
   Step 3: Record time taken to count 1 to highest number, in seconds
   Step 4: Ask patient to take three further deep breaths
   Step 5: Repeat from steps 1 to 3
  ---------------------------------------------------------------------

One may also consider the Breathlessness Screening Tool (BST) where the patient counts from 1 to 30 in their native language. Times between consecutive breaths \<8 s correlate with the risk of SpO~2~ \<95% with sensitivity/specificity of 78%/71%, while times \<5 s increase sensitivity to 91%\[[@ref48]\]

Determination of response to therapy and therapeutic escalation points {#sec2-4}
----------------------------------------------------------------------

As one moves along the respiratory management algorithm, the need arises for standardized clinical checkpoints performed with a regular frequency \[[Table 6](#T6){ref-type="table"}\]. Finally, predetermined therapeutic escalation points will be important to ensure standardized application of the algorithm across different disease acuity levels \[[Table 7](#T7){ref-type="table"}\].\[[@ref20]\]

###### 

Summary of key correlates with patient response to specific levels of oxygenation strategy/support

  Modality                           Continue HFNCImproves oxygenation and provides some added PEEP effect   Attempt awake proning for                Assisted ventilation for
  ---------------------------------- ----------------------------------------------------------------------- ---------------------------------------- -------------------------------------------------------------------------------------------
  Response to oxygen                 Good response                                                           Poor response                            Inadequate response or increased WOB
  Probable primary pathophysiology   Diffusion abnormality                                                   V/Q mismatch                             Collapsed alveoli or shunt or fragile
  Caveats                            Aerosolization risk                                                     Ensure no contraindications to proning   Ensure no contraindications to NIPPV (always factor device considerations of max. FiO~2~)
  Patient tolerability                                                                                                                                

NIPPV: Noninvasive positive pressure ventilation, HFNC: High-flow nasal cannula, PEEP: Positive end expiratory pressure, WOB: Work of breathing

###### 

Summary of important escalation points that will provide a clinically applicable framework for objective therapeutic approach transitions

  --------------------------------------------------------------------------------------------------------------
  Modality                                   Ceiling of therapy   ROX at (Hs) SpO2/FiO2/RR   Failure   Success
  ------------------------------------------ -------------------- -------------------------- --------- ---------
  HFNC\[[@ref19][@ref20][@ref48][@ref49]\]   ROX index \<3.85     2                          \<2.85    \>4.88

  6                                          \<3.47               \>4.88                               

  12                                         \<3.85               \>4.88                               

  LFNC                                       S/F ratio                                                 

  NIPPV                                      P/F ratio                                                 

  Prone                                      SCRB-60\                                                  
                                             SBC                                                       
  --------------------------------------------------------------------------------------------------------------

ROX index: Ratio of pulse oximetry/fraction of inspired oxygen to respiratory rate.\[[@ref20]\] HFNC: High-flow nasal cannula, LFNC: Low-flow nasal cannula, NIPPV: Noninvasive positive pressure ventilation, S/F ratio: SpO~2~/FiO~2~, P/F ratio: PaO~2~/FiO~2~, SBC: Single breath count

Mechanical ventilation, proning, and extracorporeal mechanical support {#sec2-5}
----------------------------------------------------------------------

Given that at least two distinct phenotypes of respiratory failure exist in COVID-19, prompt recognition of the type (L vs. H) of physiology applicable to each particular patient, followed by appropriate mechanical ventilation strategy, will be critical \[[Table 8](#T8){ref-type="table"}\].\[[@ref51][@ref52]\] In addition, early and aggressive proning strategy, beginning while the patient is still on nasal cannula oxygen therapy (i.e., a strategy aimed at preventing tracheal intubation) and continuing along the entire spectrum of respiratory failure severity, is now considered critical to achieving favorable clinical outcomes.\[[@ref2][@ref53]\] Finally, important considerations and limitations to prone positioning therapy are provided in [Table 9](#T9){ref-type="table"}. In terms of extracorporeal mechanical support, providers should follow established guidelines and appropriate patient suitability criteria to optimize clinical outcomes.\[[@ref2]\]

###### 

Summary of mechanical ventilation and proning strategies utilized in coronavirus disease-19

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ventilator strategy\[[@ref13][@ref15][@ref50][@ref52][@ref54]\]                 Proning strategy\[[@ref50][@ref51][@ref53]\]                                                    
  ------------------------------------------------------------------------------- ------------------------------------------------------------- ------------------- ------------- ----------------------------------------------
  Driving pressure                                                                \<15 cmH~2~O                                                  \>15 cmH~2~O        Indications   P/F \<50\
                                                                                                                                                                                  Driving pressure \>15 cmH~2~O\
                                                                                                                                                                                  Compliance \<40 ml/cmH~2~O

  Tidal volume                                                                    8 ml/kg                                                       6 ml/kg             Avoid if      Limited resources (PPE)\
                                                                                                                                                                                  Proning expertise not available

  If inadequate response, consider rescue measures: NMBA, diuretic, FiO~2~ ≥80%   Prerequisites                                                 Escalate PEEP\                    
                                                                                                                                                Optimize NMBA                     

  Compliance                                                                      \>40 ml/cmH~2~O                                               \<40 ml/cmH~2~O     Settings      Tidal volume 6 ml/kg\
                                                                                                                                                                                  FiO~2~ ≥60%, PEEP ≥5

  Actions                                                                         Continue same ventilatory strategy. Proning benefit unclear   Low tidal volume\   Timing        Within 6 h for patients with good prognosis\
                                                                                                                                                High PEEP\                        Within 24 h for patients with poor prognosis
                                                                                                                                                Prone positioning                 

  Phenotype                                                                       Type L                                                        Type H                            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PPE: Personal protective equipment, NMBA: Neuromuscular blocking agents, PEEP: Positive end expiratory pressure, P/F: PaO~2~/FiO~2~ ratio

###### 

Important considerations and limitations related to proning therapy

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Contraindications to prone positioning\[[@ref21]-[@ref23][@ref53]-[@ref55]\]   Ceiling of therapy for (awake) prone positioning (repeated assessments every 30 min-2 h)   
  ------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------ ----------------------------------------------------------
  Unstable spine                                                                 Facial injuries                                                                            Inability to tolerate procedure\
                                                                                                                                                                            Increased work of breathing (SBC, accessory muscle use)\
                                                                                                                                                                            Tachypnea\
                                                                                                                                                                            Hemodynamic instability\
                                                                                                                                                                            Deterioration in SCRB-60 or SBC

  Raised ICP                                                                     Morbid obesity                                                                             

  Thoracic or abdominal injuries                                                 Pregnancy                                                                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SBC: Single breath count \[[Table 5](#T5){ref-type="table"}\], SCRB-60: Clinical risk stratification score \[[Table 4](#T4){ref-type="table"}\]

SUMMARY AND CONCLUSIONS {#sec1-2}
=======================

Summative algorithms for initial management of nonintubated COVID-19 patients \[[Figure 1](#F1){ref-type="fig"}\]; basic mechanical ventilation approaches \[[Figure 2](#F2){ref-type="fig"}\]; and advanced mechanical ventilation strategies for more severely ill patients \[[Figure 3](#F3){ref-type="fig"}\] are presented at this time.\[[@ref56][@ref57][@ref58]\] In addition, one should be ready to recognize when appropriate escalation of care transitions may be required, keeping in mind that there must be a balance between indiscriminately following a "protocol" and patient-centric consideration for individual circumstances. With that in mind, standardizing documentation ensures that all teams involved in caring for the patient remain updated and aware of previous discussions, decisions, and potential changes \[[Figure 4](#F4){ref-type="fig"}\]. It is important to recognize that our understanding of SARS-CoV-2 and COVID-19 continues to evolve, and that current management strategies may change in response to increased medical and scientific knowledge of the disease process.

![Management algorithm for nonintubated coronavirus disease-2019 patients with progressive respiratory worsening. AIIR: Airborne infection isolation room, LFNC: Low-flow nasal cannula, HFNC: High-flow nasal cannula, S/F: SpO2/FiO2, P/F: PaO2/FiO2, PPE: Personal protective equipment, SpO2: Peripheral capillary oxygen saturation, RR: Respiratory rate, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, SBC: Single breath count, ?: change, NIPPV: Noninvasive ositive pressure ventilation, WOB: Work of breathing](IJCIIS-10-56-g001){#F1}

![Management algorithm for coronavirus disease 2019 patients with respiratory failure requiring mechanical ventilation. IBW: Ideal body weight, FiO2: Fraction of inspired oxygen, PEEP: Positive end expiratory pressure, P/F: PaO2/FaO2, RR: Respiratory rate, Vt: Tidal volume, SpO2: Peripheral capillary oxygen saturation, DP: Driving pressure, Cstat: Static compliance, iNO: inhaled nitrous oxide, Pplat: Plateau pressure, ABG: Arterial blood gas, See references[@ref56]57\] for ARDSnet original sources](IJCIIS-10-56-g002){#F2}

![Management algorithm for patients with severe coronavirus disease 2019 respiratory failure. NMBA: Neuromuscular blocking agents, ECLS: Extracorporeal life support, CCM: Critical care medicine, FiO2: Fraction of inspired oxygen, PEEP: Positive end expiratory pressure, Vt: Tidal volume, DP: Driving pressure, Cstat: Static compliance, HCP: Health.care provider, PPE: Personal protective equipment, P/F: PaO2/FiO2, SAPS.II: Simplified Acute Physiology score.II, APACHE.II: Acute Physiology and Chronic Health Evaluation](IJCIIS-10-56-g003){#F3}

![Treatment escalation plan checklist. ED: Emergency department, HDU: High-dependency unit, CCM: Critical care medicine, IMV: Invasive mechanical ventilation, ECLS: Extracorporeal life support, LFNC: Low-flow nasal cannula, HFNC: High-flow nasal cannula, NIPPV: Noninvasive positive pressure ventilation](IJCIIS-10-56-g004){#F4}

Special note {#sec2-6}
------------

A full discussion regarding the complex issue of monitoring and maintaining adequate oxygenation in the outpatient/home setting is beyond the scope of this document; however, a dedicated Joint ACAIM-WACEM COVID-19 Clinical Management Taskforce guideline is forthcoming with recommendations specific to the implementation of home-based oxygenation strategy in patients with isolated hypoxia and clinically mild disease.
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